Immune gene therapy for kidney cancer: The search for a magic trigger

Molecular Therapy

Volumn 7, Issue 2, 2003, Pages 153-154

  Kim, Hyung L ^a   Belldegrun, Arie S ^a   Figlin, Robert A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CARBONATE DEHYDRATASE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; PLASMID VECTOR; TUMOR VACCINE;

ANTIGEN PRESENTATION; CANCER SURVIVAL; CELL MEDIATED CYTOTOXICITY; DENDRITIC CELL; GENE DELIVERY SYSTEM; GENE THERAPY; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOTHERAPY; KIDNEY CARCINOMA; METASTASIS; REVIEW; TUMOR IMMUNITY;

EID: 0037302728     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-0016(02)00048-5     Document Type: Review

References (25)

1. Jemal, A., et al. (2002). Cancer statistics, 2002. CA Cancer J. Clin. 52: 23-47.
2. Kirkali, Z., Tuzel, E., and Mungan, M. U. (2001). Recent advances in kidney cancer and metastatic disease. BJU Int. 88: 818-824.
3. Vogelzang, N. J., and Stadler, W. M. (1998). Kidney cancer. Lancet 352: 1691-1696.
4. Oliver, R. T., et al. (1988). A phase 2 study of surveillance in patients with metastatic renal cell carcinoma and assessment of response of such patients to therapy on progression. Mol. Biother. 1: 14-20.
5. Franzke, A., et al. (1999). Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. J. Clin. Oncol. 17: 529-533.
6. Bukowski, R. M. (2000). Cytokine combinations: therapeutic use in patients with advanced renal cell carcinoma. Semin. Oncol. 27: 204-212.
7. Fisher, R. I., et al. (1997). High-dose aldesleukin in renal cell carcinoma: long-term survival update. Cancer J. Sci. Am. 3 (Suppl. 1): 570-72.
8. Figlin, R. A. (1999). Renal cell carcinoma: management of advanced disease. J. Urol. 161: 381-386; discussion 386-387.
9. Neumann, E., et al. (1998). Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies? Cancer Res. 58: 4090-4095.
10. Bui, M. H., et al. (2002). Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin. Cancer Res. (in press).
11. Oosterwijk, E., et al. (1986). Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int. J. Cancer 38: 489-494.
12. Uchida, A., and Fukata, H. (1993). Role of NK cell cytotoxic factor against fresh human tumors. Nat. Immun. 12: 267-278.
13. Dummer, R. (2001). GVAX (Cell Genesys). Curr. Opin. Invest. Drugs 2: 844-848.
14. Hoffman, D. M., and Figlin, R. A. (2000). Intratumoral interleukin 2 for renal-cell carcinoma by direct gene transfer of a plasmid DNA/DMRIE/DOPE lipid complex. World J. Urol. 18: 152-156.
15. Irving, B. A., Chan, A. C., and Weiss, A. (1993). Functional characterization of a signal transducing motif present in the T cell antigen receptor zeta chain. J. Exp. Med. 177: 1093-1103.
16. Chan, A. C., Irving, B. A., and Weiss, A. (1992). New insights into T-cell antigen receptor structure and signal transduction. Curr. Opin. Immunol. 4: 246-251.
17. Banchereau, J., and Steinman, R. M. (1998). Dendritic cells and the control of immunity. Nature 392: 245-252.
18. Geiger, J. D., et al. (2001). Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res. 61: 8513-8519.
19. Mulders, P., et al. (1999). Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines. Clin. Cancer Res. 5: 445-454.
20. Thurnher, M., et al. (1996). Human renal-cell carcinoma tissue contains dendritic cells. Int. J. Cancer 68: 1-7.
21. Troy, A. J., et al. (1998). Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin. Cancer Res. 4: 585-593.
22. Shimizu, K., et al. (1999). Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. Proc. Natl. Acad Sci. USA 96: 2268-2273.
23. Tso, C. L., et al. (2001). Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor. Cancer Res. 61: 7925-7933.
24. Soiffer, R., et al. (1998). Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 95: 13141-13146.
25. Kielian, T., et al. (1999). Granulocyte/macrophage-colony-stimulating factor released by adenovirally transduced CT26 cells leads to the local expression of macrophage inflammatory protein 1 alpha and accumulation of dendritic cells at vaccination sites in vivo. Cancer Immunol. Immunother. 48: 123-131.